SIGA Technologies Inc
NASDAQ:SIGA
SIGA Technologies Inc
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
Revenue Growth: Product sales for the first nine months of 2025 were approximately $86 million, up from $54 million in the same period last year.
Quarterly Volatility: Q3 was described as a quiet quarter following a strong Q2, with management emphasizing that quarterly fluctuations are normal in SIGA's business.
Balance Sheet Strength: SIGA ended Q3 with $172 million in cash and no debt, giving the company significant flexibility.
Ongoing Government Engagement: The company continues active discussions with U.S. and international governments regarding future procurement of TPOXX, despite some minor delays linked to the U.S. government shutdown.
Pipeline Progress: Key late-stage development programs, including pediatric and post-exposure prophylaxis (PEP) indications for TPOXX, continue to advance, with FDA submissions targeted for 2026.
Shareholder Returns: Since 2020, SIGA has returned about $230 million to shareholders through dividends and buybacks.
